Dr. George Simeakis | Medicine and Health Sciences | Best Researcher Award
Consultant Endocrinologist 401 General Military Hospital of Athens Greece
Dr. George Simeakis is a dedicated Greek endocrinologist with a remarkable career spanning over a decade. Currently serving as a Consultant Endocrinologist and Training Program Coordinator at the 401 General Military Hospital of Athens, he specializes in thyroid cancer and endocrine neoplasia. His contributions to thyroid cancer management and advanced endocrinology have made him a respected figure in his field.
Profile
Education 🎓
- Ph.D. (Athens University School of Medicine, 2014–2024): Focused on the effects of glucocorticoids on bone metabolism in multiple sclerosis patients.
- Subspecialty training in Thyroid Cancer (Alexandra Hospital, Athens, 2019–2021).
- Visiting Fellow (Thyroid Oncology, Pisa, Italy, 2021).
- Residency in Endocrinology (Alexandra Hospital, Athens).
- Residency in Internal Medicine (401 General Military Hospital, Athens).
Experience 💼
- Teacher, National and Kapodistrian University of Athens (Postgraduate Program in Endocrine Neoplasias, 2023–Present).
- Consultant Endocrinologist, Thyroid Cancer Outpatient Clinic (2021–Present).
- Training Program Coordinator, 401 General Military Hospital.
- Private Practice Endocrinologist (Since 2013).
- Sub-investigator and researcher in groundbreaking projects on thyroid cancer, circulating tumor markers, and more.
Research Interests 🔬
Dr. Simeakis’s research focuses on:
- Thyroid cancer diagnostics and treatment, including radiofrequency ablation techniques.
- Circulating tumor DNA (ctDNA) and cells (CTCs) in endocrine malignancies.
- Bone health in autoimmune disorders like multiple sclerosis.
Awards & Honors 🏆
- D. Ikkos Award (2024): Best publication in clinical endocrinology.
- Chairmanship of Basic Cancer Symposium, 46th European Thyroid Association Meeting (2024).
- Discussion Leader, Medullary Thyroid Cancer Poster Session (2024).
Publications Top Notes: 📚
“Radiofrequency Ablation for Locoregional Structural Incomplete Response in Differentiated Thyroid Cancer: Initial Experience in Greece”
Biomedicines, 2025. Read here
Cited by: 12 articles.
“Metastatic Medullary Thyroid Carcinoma: Disease Course, Treatment Modalities and Drug Resistance”
Endocrine, 2023. Read here
Cited by: 25 articles.
“High-Dose Intravenous Steroid Treatment in Newly Diagnosed Multiple Sclerosis Patients: A Pilot Study”
Biomedicines, 2023. Read here
Cited by: 15 articles.
“Management of Endocrine Disease: Medullary Thyroid Cancer and Future Perspectives”
European Journal of Endocrinology, 2022. Read here
Cited by: 20 articles.